Αρχειοθήκη ιστολογίου

Τετάρτη 21 Μαρτίου 2018

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer

Hill, AG; Findlay, M; Burge, M; Jackson, C; García Alfonso, P; Samuel, L; Ganju, V; ... Tabernero, J; + view all Hill, AG; Findlay, M; Burge, M; Jackson, C; García Alfonso, P; Samuel, L; Ganju, V; Karthaus, M; Amatu, A; Jeffery, M; Di Bartolomeo, M; Bridgewater, J; Coveler, AL; Hidalgo, M; Kapp, AV; Sufan, R; McCall, B; Hanley, W; Penuel, E; Pirzkall, A; Tabernero, J; - view fewer (2018) Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer. Clinical Cancer Research 10.1158/1078-0432.CCR-17-0646 . (In press).

http://ift.tt/2FMPkT4

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου